Xue-Jun (June) Kong, M.D. Principal Investigator and Director of Synapse Autism program at Martinos Center/Mass General Hospital, Principal Investigator and Attending Physician at Beth Israel Deaconess Medical Center, Assistant Professor of Harvard Medical School. She leads her Autism research team, the research projects involve ASD microbiome and genomic study, biomarkers, autonomic dysfunction, eye-tracking, and brain imaging, non-invasive brain stimulation, drug clinical trials, aiming better understanding the etiology, early detection, clinical subgrouping, evidence based and target treatments of ASD, filed six patents as inventor or co-inventor at MGH. She proposed and modified ASD primary care model and extensive medical evaluation protocol, also established east meets west protocol for ASD as a certified MD acupuncturist.



Select Publications

Kong XJ, Kang J, Liu K. Probiotic and intra-nasal oxytocin combination therapy on autonomic function and gut-brain axis signaling in young children and teens with autism spectrum disorder. J Psychiatr Res. 2023 Aug 12;166:1-9. doi: 10.1016/j.jpsychires.2023.08.006. Epub ahead of print. PMID: 37639877.

Binbin Sun, Bryan Wang, Zhen Wei, Zhe Feng, Zhi-Liu Wu, Walid Yassin, William S. Stone, Xue-Jun Kong* Identification of Diagnostic Markers for ASD: A Restrictive Interest Analysis Based on EEG Combined with Eye Tracking. Front Neuroscience 2023 https://doi.org/10.3389/fnins.2023.1236637

Hannah Tayla Sherman , Kevin Liu , Kenneth Kwong , Suk‐Tak Chan , Alice Chukun Li and Xue‐Jun Kong. Carbon monoxide (CO) correlates with symptom severity, autoimmunity, and responses to probiotics treatment in a cohort of children with autism spectrum disorder (ASD): a post‐hoc analysis of a randomized controlled trial. BMC Psychiatry (2022) 22:536 https://doi.org/10.1186/s12888-022-04151-3.

Kong, X. J., Liu, J., Liu, K., Koh, M., Sherman, H., Liu, S., … & Song, Y. (2021). Probiotic and Oxytocin Combination Therapy in Patients with Autism Spectrum Disorder: A Randomized, Double-Blinded, Placebo-Controlled Pilot Trial. Nutrients, 13(5), 1552.s


Inventor: Methods and Composition for the Treatment of Prader-Willi Syndrome Symptoms. U.S. Patent Application No. 63/127,936, filed on Dec.18th 2020. MGH 125141.03558 Licensed to industry 2021-2022 via MGH IP

Inventor: Methods and Composition for the Treatment of Autism Spectrum Disorder. U.S. Provisional Application No. 63/132,081, filed Dec.30th 2020. MGH 125141.03569 In licensing process via MGH IP

Co-Inventor: Methods of Early Identification and Intervention for high-risk neonates who otherwise will develop autistic social impairment later in life. U.S Provisional Application No.63376780, filed June 2nd, 2022. 125141.0410#MGH2022-383 Under exclusive option licensing agreement via MGH IP


Synapse Lab